Where Tech Meets Bio | BiopharmaTrend | Substack

Big Pharma’s China Deal Wave & 12 Companies on Our Radar

A snap look at some of the deal dynamics and company platforms pulling global pharma toward China

24 hrs ago • BiopharmaTrend

How 2026 Started: First-Weeks Readout on AI, Pharma, & Policy

Early-year overview spanning virtual cell modeling, AI workflow plumbing in R&D and healthcare, obesity-driven capital and licensing, patent-cliff…

Feb 6 • BiopharmaTrend

Weekly Tech+Bio Highlights #71: More China Deals

DeepMind's new deep learning model lands in Nature, Big Pharma's $18B+ plans for China, FDA clears first epigenetic reprogramming trial

Feb 2 • Roman Kasianov and BiopharmaTrend

Weekly Tech+Bio Highlights #70: Signals from a Quieter Week

Isomorphic Labs x J&J platform deal, LLM “gym” for pharma R&D, Absci’s new antibody model, and more

Jan 26 • Roman Kasianov and BiopharmaTrend

Weekly Tech+Bio Highlights #69: Big Pharma Keeps Tapping Multimodal AI Stacks

JPM takeaways; reality check on de novo antibody design; 2026 biotech & clinical AI reports, and more

Jan 19 • Roman Kasianov and BiopharmaTrend

Most Popular

2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic

Jan 15 • BiopharmaTrend

Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape

Nov 20, 2025 • Andrii Buvailo, PhD

New LLMs, Agents, and Graphs in Life Sciences

Nov 6, 2025 • BiopharmaTrend

The '4th Wave' of AI Drug Discovery is Here, According to This Report

Dec 12, 2024 • Andrii Buvailo, PhD

Join 11k+ biotech industry professionals tracking strategy signals in the 'techbio' space

Sponsored Features

On Predicting Probability of Technical and Regulatory Success With AI

Insights from The American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Nov 7, 2024 • BiopharmaTrend

Using AI to Predict the Probability of Success in Drug Development

ALSO: Patented AI Platform Identifies Promising Early-Stage Biopharma Assets and Companies

Jun 13, 2024

Building Data Infrastructure for Biology

ALSO: Featuring Omics Solution Providers Market Map, from Multiomics to Spatial Biology

May 23, 2024

49:15

Enabling Precision Medicine with AI

A Deep Dive with Lantern Pharma's CEO, Panna Sharma

Mar 7, 2024 • Andrii Buvailo, PhD

Deep Dives

Big Pharma’s China Deal Wave & 12 Companies on Our Radar

A snap look at some of the deal dynamics and company platforms pulling global pharma toward China

24 hrs ago • BiopharmaTrend

How 2026 Started: First-Weeks Readout on AI, Pharma, & Policy

Early-year overview spanning virtual cell modeling, AI workflow plumbing in R&D and healthcare, obesity-driven capital and licensing, patent-cliff…

Feb 6 • BiopharmaTrend

2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic

Forward signals for 2026—from >$1.3B in tracked financings led by Neuralink’s $650M round to a shoebox-sized biocomputer, driven device control, speech…

Jan 15 • BiopharmaTrend

Aging, AI, and the Uneven Road to Longevity Medicine

Echoing notes from ARDD2025, we briefly overview geroscience, its fusion with AI, what companies pursue in this field and limitations on the way of…

Dec 11, 2025 • BiopharmaTrend

Generative Diffusion in Molecular Design

A quick field guide to diffusion-based generators in molecular design—how they work, where they complement transformers, and who is deploying them today

Nov 27, 2025 • BiopharmaTrend

Recommendations

Special Competitive Studies Project

SCSP

The Connected Ideas Project

Alexander Titus

Michael Spencer

Noah Smith

Recent posts

2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic

Forward signals for 2026—from >$1.3B in tracked financings led by Neuralink’s $650M round to a shoebox-sized biocomputer, driven device control, speech…

Jan 15 • BiopharmaTrend

Weekly Tech+Bio Highlights #68: 2026 Opens Hot With M&As, Mega-Rounds, and Model Deployments

A first read on deal flow, platform launches, and strategic intent emerging as JPM week sets the tone for early 2026

Jan 13 • BiopharmaTrend and Roman Kasianov

Weekly Tech+Bio Highlights #67: Wrapping Up 2025

First-wave AI drug builder steps back from the clinic, platform-native developer heads for IPO, a model-discovered drug enters Phase 1, & pharma…

Dec 24, 2025 • Roman Kasianov and BiopharmaTrend

Weekly Tech+Bio Highlights #66: AI Antibody Startup Hits Unicorn Status

Merck & Nvidia Debut Open-Source Drug Model; Microsoft’s Spatial Proteomics, & First Non-Profit Gets FDA Approval for Gene Therapy

Dec 15, 2025 • Roman Kasianov and BiopharmaTrend

The latest from

BiopharmaTrend

Big Pharma’s China Deal Wave & 12 Companies on Our Radar

Roman Kasianov

Weekly Tech+Bio Highlights #71: More China Deals

Andrii Buvailo, PhD

Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts